These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 22952428)

  • 1. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.
    Candolfi M; King GD; Yagiz K; Curtin JF; Mineharu Y; Muhammad AK; Foulad D; Kroeger KM; Barnett N; Josien R; Lowenstein PR; Castro MG
    Neoplasia; 2012 Aug; 14(8):757-70. PubMed ID: 22952428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design.
    Mineharu Y; King GD; Muhammad AK; Bannykh S; Kroeger KM; Liu C; Lowenstein PR; Castro MG
    Clin Cancer Res; 2011 Jul; 17(14):4705-18. PubMed ID: 21632862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
    Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
    Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
    Candolfi M; Yagiz K; Foulad D; Alzadeh GE; Tesarfreund M; Muhammad AK; Puntel M; Kroeger KM; Liu C; Lee S; Curtin JF; King GD; Lerner J; Sato K; Mineharu Y; Xiong W; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Jul; 15(13):4401-14. PubMed ID: 19570774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.
    Mineharu Y; Kamran N; Lowenstein PR; Castro MG
    Mol Cancer Ther; 2014 Dec; 13(12):3024-36. PubMed ID: 25256739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMGB1 mediates endogenous TLR2 activation and brain tumor regression.
    Curtin JF; Liu N; Candolfi M; Xiong W; Assi H; Yagiz K; Edwards MR; Michelsen KS; Kroeger KM; Liu C; Muhammad AK; Clark MC; Arditi M; Comin-Anduix B; Ribas A; Lowenstein PR; Castro MG
    PLoS Med; 2009 Jan; 6(1):e10. PubMed ID: 19143470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
    Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
    PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
    Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.
    King GD; Kroeger KM; Bresee CJ; Candolfi M; Liu C; Manalo CM; Muhammad AK; Pechnick RN; Lowenstein PR; Castro MG
    Mol Ther; 2008 Apr; 16(4):682-90. PubMed ID: 18283279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma.
    Candolfi M; Curtin JF; Yagiz K; Assi H; Wibowo MK; Alzadeh GE; Foulad D; Muhammad AK; Salehi S; Keech N; Puntel M; Liu C; Sanderson NR; Kroeger KM; Dunn R; Martins G; Lowenstein PR; Castro MG
    Neoplasia; 2011 Oct; 13(10):947-60. PubMed ID: 22028620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.
    Puntel M; Muhammad AK; Candolfi M; Salem A; Yagiz K; Farrokhi C; Kroeger KM; Xiong W; Curtin JF; Liu C; Bondale NS; Lerner J; Pechnick RN; Palmer D; Ng P; Lowenstein PR; Castro MG
    J Virol; 2010 Jun; 84(12):6007-17. PubMed ID: 20375153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.
    King GD; Muhammad AK; Larocque D; Kelson KR; Xiong W; Liu C; Sanderson NS; Kroeger KM; Castro MG; Lowenstein PR
    Mol Ther; 2011 Oct; 19(10):1793-801. PubMed ID: 21505426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.
    King GD; Muhammad AK; Curtin JF; Barcia C; Puntel M; Liu C; Honig SB; Candolfi M; Mondkar S; Lowenstein PR; Castro MG
    Neuro Oncol; 2008 Feb; 10(1):19-31. PubMed ID: 18079358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.
    Kawashita Y; Deb NJ; Garg M; Kabarriti R; Alfieri A; Takahashi M; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):191-200. PubMed ID: 24972258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
    Candolfi M; Yagiz K; Wibowo M; Ahlzadeh GE; Puntel M; Ghiasi H; Kamran N; Paran C; Lowenstein PR; Castro MG
    Clin Cancer Res; 2014 Mar; 20(6):1555-1565. PubMed ID: 24501391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.
    Xiong W; Candolfi M; Liu C; Muhammad AK; Yagiz K; Puntel M; Moore PF; Avalos J; Young JD; Khan D; Donelson R; Pluhar GE; Ohlfest JR; Wawrowsky K; Lowenstein PR; Castro MG
    PLoS One; 2010 Jun; 5(6):e11074. PubMed ID: 20552015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
    Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Efficacy and Safety Profile of Allometrically Scaled Doses of Doxycycline Used to Turn "On" Therapeutic Transgene Expression from High-Capacity Adenoviral Vectors in a Glioma Model.
    VanderVeen N; Raja N; Yi E; Appelman H; Ng P; Palmer D; Zamler D; Dzaman M; Lowenstein PR; Castro MG
    Hum Gene Ther Methods; 2016 Jun; 27(3):98-111. PubMed ID: 27056322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.
    Chang JW; Lee H; Kim E; Lee Y; Chung SS; Kim JH
    Neurosurgery; 2000 Oct; 47(4):931-8; discussion 938-9. PubMed ID: 11014433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
    Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG
    Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.